394 related articles for article (PubMed ID: 15717742)
1. Cardiac safety of liposomal anthracyclines.
Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
Alberts DS; Muggia FM; Carmichael J; Winer EP; Jahanzeb M; Venook AP; Skubitz KM; Rivera E; Sparano JA; DiBella NJ; Stewart SJ; Kavanagh JJ; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):53-90. PubMed ID: 15717738
[TBL] [Abstract][Full Text] [Related]
3. Use of liposomal anthracyclines in Kaposi's sarcoma.
Krown SE; Northfelt DW; Osoba D; Stewart JS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):36-52. PubMed ID: 15717737
[TBL] [Abstract][Full Text] [Related]
4. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Robert NJ; Vogel CL; Henderson IC; Sparano JA; Moore MR; Silverman P; Overmoyer BA; Shapiro CL; Park JW; Colbern GT; Winer EP; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):106-46. PubMed ID: 15717740
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety of liposomal anthracyclines.
Safra T
Oncologist; 2003; 8 Suppl 2():17-24. PubMed ID: 13679592
[TBL] [Abstract][Full Text] [Related]
6. Liposomal anthracycline administration and toxicity management: a nursing perspective.
Wood LS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):182-90. PubMed ID: 15717743
[TBL] [Abstract][Full Text] [Related]
7. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
[TBL] [Abstract][Full Text] [Related]
8. Role of liposomal anthracyclines in the treatment of multiple myeloma.
Hussein MA; Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 13):147-60. PubMed ID: 15717741
[TBL] [Abstract][Full Text] [Related]
9. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
10. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
11. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.
Stavridi F; Palmieri C
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1859-69. PubMed ID: 19046106
[TBL] [Abstract][Full Text] [Related]
13. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
14. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
[TBL] [Abstract][Full Text] [Related]
15. Advantages of liposomal delivery systems for anthracyclines.
Allen TM; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):5-15. PubMed ID: 15717735
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics of liposomal anthracycline therapy.
Bennett CL; Calhoun EA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):191-5. PubMed ID: 15717744
[TBL] [Abstract][Full Text] [Related]
17. Liposomal anthracyclines in metastatic breast cancer: clinical update.
Rivera E
Oncologist; 2003; 8 Suppl 2():3-9. PubMed ID: 13679590
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
[TBL] [Abstract][Full Text] [Related]
19. Liposomal anthracyclines for breast cancer.
Sparano JA; Winer EP
Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
[TBL] [Abstract][Full Text] [Related]
20. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Caballero Romero Á; Delgado Ureña MT; Salmerón García A; Megías Fernández MT; Librada Porriño-Bustamante M; Cabeza Barrera J
Anticancer Drugs; 2018 Oct; 29(9):821-826. PubMed ID: 30036190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]